

**Adult CIRB – Early Phase Emphasis
Meeting Agenda**

Tuesday, December 5, 2017

I Initial Review

10170, A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (Protocol Version Date 10/06/17)

II Initial Review

10126, A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma (Protocol Version Date 10/23/17)

III Amendment Review

9938, Phase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors (Protocol Version Date 11/07/17)

IV Continuing Review

9875, Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (Protocol Version Date 10/03/17)

V Continuing Review

9892, Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer (Protocol Version Date 03/21/16 Update Date 04/18/16)

VI Continuing Review

9938, Phase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors (Protocol Version Date 11/07/17)

VII Continuing Review

10005, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma (Protocol Version Date 08/23/17)

VIII Continuing Review

10010, A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer (Protocol Version Date 06/09/17)
